医学
免疫疗法
癌症
食管癌
生物标志物
肿瘤科
化疗
内科学
临床试验
食管
癌症免疫疗法
胃食管交界处
腺癌
生物
生物化学
作者
Bülent Çetin,Chiara A. Wabl,Özge Gümüşay
出处
期刊:Immunotherapy
[Future Medicine]
日期:2023-08-01
卷期号:15 (12): 945-962
标识
DOI:10.2217/imt-2022-0287
摘要
The impact of checkpoint inhibitors on gastroesophageal cancer treatment has been tremendous in the last 2 years. KEYNOTE-590, CHECKMATE 649 and CheckMate 648 are landmark trials that have introduced immunotherapy to the field as first-line therapy, leading to a paradigm change for advanced esophageal and gastric cancer. Chemotherapy in combination with immunotherapy is now the standard of care for first-line treatment of locally advanced or metastatic adenocarcinoma of the esophagus, esophagogastric junction and stomach. Several new targets and treatments are available for gastroesophageal cancer that are based on the characterization of cancer cells and the tumor microenvironment. Biomarker-based therapy selection is critical to optimize outcomes and minimize toxicities, as well as give insight into the optimal timing and sequence of a patient's treatment course.
科研通智能强力驱动
Strongly Powered by AbleSci AI